RxDoctor Payments Data

Luis Barba, MD

General Practice · Orange City, FLNPI 1992178750

Payments from drug & device makers

$4,285in general payments, 2019–2025

Across 232 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$942
  • GSK$575
  • AstraZeneca$519
  • Boehringer Ingelheim$344
  • Pfizer$307
  • Lilly USA, LLC$267
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,285 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$27,828
Medicare patients
59
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$83,715
FarxigaDapagliflozin Propanediol39$57,942
EntrestoSacubitril/Valsartan35$56,751
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,751
JardianceEmpagliflozin31$45,531
Diclofenac Sodium124$43,274
DovatoDolutegravir Sodium/Lamivudine13$41,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$38,599
JanuviaSitagliptin Phosphate24$34,179
MounjaroTirzepatide19$28,285
JanumetSitagliptin Phos/Metformin Hcl16$23,519
UbrelvyUbrogepant13$20,552
XareltoRivaroxaban11$17,444
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$16,804
LinzessLinaclotide15$16,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$307$83,71594 claims
AstraZenecaFarxiga, Breztri Aerosphere$519$74,74659 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$344$62,49558 claims
MerckJanuvia, Janumet$43$57,69840 claims
NovartisEntresto$236$56,75135 claims
GileadBiktarvy$16$45,75112 claims
GSKTrelegy Ellipta$575$38,59941 claims
AbbVieUbrelvy, Linzess$942$36,87228 claims
Lilly USA, LLCMounjaro$267$28,28519 claims
Johnson & JohnsonXarelto$160$17,44411 claims
Novo NordiskOzempic$88$13,30615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →